Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest 2-Oxazolidone Stories

2013-12-20 00:20:36

-- Begins Phase 2 Clinical Study in China, Phase 1 Bridging Study in Australia -- HAYWARD, Calif. and SHANGHAI, Dec. 19, 2013 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the initiation of a global clinical development program for its lead compound MRX-I, a novel oxazolidinone antibiotic for treatment of Gram-positive infections including methicillin-resistant Staphylococcus aureus...

2013-08-22 04:21:55

-- Funds U.S. Development of MRX-I Next-Generation Antibiotic -- HAYWARD, Calif. and SHANGHAI, Aug. 22, 2013 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced it raised $25 million in Series B financing. Led by BVCF, a private equity and growth fund specializing in the life sciences industry, the round also includes existing investors Morningside Group and Devon Park Bioventures. Proceeds...

2013-02-13 10:26:33

Treatment with a newer antibiotic, tedizolid phosphate, once daily for 6 days was statistically noninferior (no worse than) in efficacy to the antibiotic linezolid twice daily for 10 days for both early (at day 2 to 3) and sustained (at day 11) clinical responses in patients with acute bacterial skin and skin structure infections, according to a study appearing in the February 13 issue of JAMA. "Antimicrobials available for treatment of complicated skin and skin structure infections...

2012-10-24 07:32:22

HAYWARD, Calif. and SHANGHAI, Oct. 24, 2012 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, and Shanghai Zhangjiang Biomedical Industry Venture Capital today announced the establishment of Shanghai MengKe Pharmaceuticals, Inc., a joint venture formed to fund the development and commercialization of MRX-I for the Chinese market. MRX-I is a novel, oral oxazolidinone antibiotic targeting infections due to...

2012-04-22 22:20:49

HAYWARD, Calif. and SHANGHAI, April 23, 2012 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the completion of its Phase 1 clinical trial for MRX-I, its first development-stage antibiotic drug candidate. The agent MRX-I, an oral oxazolidinone antibiotic, targets infections due to multi-drug resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and...

2010-10-04 07:00:00

SAN DIEGO, Oct. 4 /PRNewswire/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will participate in a panel discussion on antibiotic drug development at Citi's 5th Annual Biotech Day. The panel titled, How to Kill Superbugs: Novel Antibiotics to Hit Drug Resistant Bacteria, will take place at 2:00 p.m. ET on Tuesday, October 5th at the Westin Waterfront Hotel in Boston. About Trius...

2010-09-13 15:00:00

SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) today reported new findings on torezolid phosphate (TR-701), a second generation oxazolidinone antibiotic now in Phase 3 clinical development. The data elucidate the mechanism by which torezolid retains full activity against clinical isolates of Staphylococcus aureus (S. aureus) carrying the cfr gene which confers resistance to first generation oxazolidinones such as linezolid, marketed by Pfizer as...

2010-06-28 09:26:00

WALTHAM, Mass., June 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of two emerging agents from Forest/AstraZeneca/Takeda and Trius will drive the methicillin-resistant Staphylococcus aureus (MRSA) drug market to increase from $631 million in 2009 to $752 million in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The Pharmacor 2010 findings...

2010-06-16 07:00:00

SAN DIEGO, June 16 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its planned Phase 3 study for the oral dosage form of torezolid phosphate for treatment of acute bacterial skin and skin structure infections (ABSSSI). The double-blind pivotal study will compare the efficacy and safety of once-daily oral administration of...

2010-03-29 15:15:00

SAN DIEGO, March 29 /PRNewswire/ -- Trius Therapeutics, Inc. today announced results from its Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of the intravenous (IV) dosage form of torezolid phosphate, an IV and orally administered second generation oxazolidinone for the treatment of serious gram positive infections, including methicillin-resistant Staphylococcus aureus (MRSA). The trial achieved its primary goal of establishing the safety and tolerability...